- The FDA has approved Pharmacyclics' (PCYC) ibrutinib for mantle cell lymphoma.
- The drug is co-marketed with Janssen (JNJ).
- This marks the second drug with Breakthrough Therapy Designation to win approval.
- The drug is "intended for patients who have received at least one prior therapy."
- Also approved for MCL: Celgene's (CELG) Revlimid.
- Full FDA release